JPH1085303A - Integrally-formed container for eye drops - Google Patents
Integrally-formed container for eye dropsInfo
- Publication number
- JPH1085303A JPH1085303A JP8244359A JP24435996A JPH1085303A JP H1085303 A JPH1085303 A JP H1085303A JP 8244359 A JP8244359 A JP 8244359A JP 24435996 A JP24435996 A JP 24435996A JP H1085303 A JPH1085303 A JP H1085303A
- Authority
- JP
- Japan
- Prior art keywords
- container
- eye drops
- vinyl acetate
- resin
- polyolefin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title abstract description 21
- 229940012356 eye drops Drugs 0.000 title abstract description 20
- -1 i.e. Substances 0.000 claims abstract description 13
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920000098 polyolefin Polymers 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 8
- 239000011347 resin Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000005038 ethylene vinyl acetate Substances 0.000 claims abstract description 6
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims abstract description 6
- 239000002997 ophthalmic solution Substances 0.000 claims description 17
- 229940054534 ophthalmic solution Drugs 0.000 claims description 17
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 239000012611 container material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000003086 colorant Substances 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229920005672 polyolefin resin Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 238000009834 vaporization Methods 0.000 abstract 1
- 230000008016 vaporization Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000463 material Substances 0.000 description 12
- 239000008213 purified water Substances 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000007599 discharging Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 240000007108 Fuchsia magellanica Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000122235 Junco hyemalis Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- LARLNXOUTTUXPN-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(5-methyl-1,2-oxazol-3-yl)azanide Chemical compound [Na+].O1C(C)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 LARLNXOUTTUXPN-UHFFFAOYSA-N 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940045613 taurine 1000 mg Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、点眼剤用容器に関す
る。The present invention relates to a container for eye drops.
【０００２】[0002]
【従来の技術】近年、小容量の点眼剤が種々発売されて
いる。それらの１回〜数回で使い切る種類の点眼剤のう
ち防腐剤を配合しないものは、コンタクトレンズ使用時
にもそのまま点眼できる他、眼への刺激が弱いため、知
覚過敏なドライアイなどの症状に特に有効である。2. Description of the Related Art In recent years, various eye drops having a small volume have been put on the market. Of these types of eye drops that can be used up once or several times, those that do not contain preservatives can be instilled as they are when using contact lenses, and are less irritating to the eyes, causing symptoms such as hypersensitive dry eye Especially effective.
【０００３】それらの小容量の点眼剤用の容器として特
開平８−３４４８９号公報などに記載された一体成形型
（成形充填同時システム）の容器などが知られている。[0003] As a container for such small-volume eye drops, there is known an integrally molded type (simultaneous molding and filling system) container and the like described in JP-A-8-34489.
【０００４】[0004]
【発明が解決しようとする課題】前述したような小容量
の点眼剤は、容器の大きさが小さいため、スクイズ、す
なわち内容液を押し出すのに手指に力を要するという問
題があった。このことから、より容易に内容液を滴下で
きる容器が望まれていた。ここで、容器の素材を単に柔
らかい素材に変更すればスクイズ力は減少するが、通常
用いられる素材では水分揮散が多くなってしまい内容液
の安定性に問題がある。水分揮散の抑制のためにはプラ
スチック包装、アルミ包装などの技術が知られている
が、いずれも繁雑であるうえ、結露を生じさせてしまう
などの問題点もある。また、一体成形型点眼剤用容器
は、その製造工程において、ポリオレフィン以外の素材
では成形が困難であるという欠点もあった。The above-mentioned small-volume eye drops have a problem that, since the size of the container is small, a squeeze, that is, a force is required on the fingers to push out the content liquid. For this reason, a container that allows the content liquid to be dripped more easily has been desired. Here, if the material of the container is simply changed to a soft material, the squeezing force is reduced. However, in the case of a commonly used material, the evaporation of water is increased and there is a problem in the stability of the liquid content. Techniques such as plastic packaging and aluminum packaging are known for suppressing moisture evaporation, but all of them are complicated and have problems such as dew condensation. In addition, the integrally molded ophthalmic container has a drawback that it is difficult to mold a material other than polyolefin in the manufacturing process.
【０００５】本発明の目的は、一体成形型の点眼剤用容
器の提供にあたり、スクイズ性、液出し性に優れ、かつ
内容液を安定に保存できる、成形の容易な点眼剤容器を
提供することにある。An object of the present invention is to provide an easily-moldable ophthalmic solution container which is excellent in squeezing property and liquid discharging property and can stably store the content liquid, in providing an integrally molded type ophthalmic solution container. It is in.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、目的を達
成するため種々検討した結果、ポリオレフィンにエチレ
ンビニルアセテート共重合体を配合した樹脂の容器を使
用した点眼剤は、スクイズ性、内容液の液出し性が良好
で、かつ経時的な水分揮散の少ない安定な点眼剤となる
うえ、容器製造時には従来と同様の方法で成形できるこ
とを見いだし本発明を完成した。Means for Solving the Problems The present inventors have conducted various studies to achieve the object. As a result, eye drops using a resin container in which an ethylene vinyl acetate copolymer is blended with a polyolefin have been found to have squeezing properties and content. The present invention has been found to be a stable eye drop which has a good liquid drainage property and little evaporation of water over time, and can be molded by the same method as in the related art at the time of manufacturing a container, thereby completing the present invention.
【０００７】すなわち、本発明は、ポリオレフィンにエ
チレンビニルアセテート共重合体を配合した樹脂からな
ることを特徴とする一体成形型点眼剤用容器である。That is, the present invention is an integrally molded ophthalmic container comprising a resin obtained by mixing an ethylene vinyl acetate copolymer with a polyolefin.
【０００８】[0008]
【発明の実施の形態】本発明において一体成形型点眼剤
容器とは成形充填同時システムにより製造される容器で
ある。具体的には特開平８−３４４８９号公報などに記
載されているものなどがあげられ、同公報に記載された
方法などにより製造することができる。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, an integrally molded ophthalmic container is a container produced by a simultaneous molding and filling system. Specific examples include those described in JP-A-8-34489 and the like, and they can be produced by the method described in the publication.
【０００９】本発明の一体成形型点眼剤容器は、容器の
形状は特に関与しない。しかし、内容量が２ｍｌを越え
る容器のときは、ポリオレフィンのみで成形された容器
でもスクイズ力は充分小さいので本発明が必要となるこ
とは少ない。また、容器の肉厚は０．３〜１．２ｍｍが
好ましく、もっとも好ましいのは０．６ｍｍである。肉
厚が０．３ｍｍ未満であると水分揮散が多くなり、１．
２ｍｍを越えるとスクイズ力が大きくなってしまう。[0009] The shape of the container is not particularly involved in the integrally formed ophthalmic solution container of the present invention. However, in the case of a container having an internal volume exceeding 2 ml, the squeezing force is sufficiently small even in a container formed of only polyolefin, so that the present invention is rarely required. The thickness of the container is preferably 0.3 to 1.2 mm, and most preferably 0.6 mm. If the wall thickness is less than 0.3 mm, water evaporation will increase, and
If it exceeds 2 mm, the squeeze force will increase.
【００１０】本発明の容器に用いる素材はエチレンビニ
ルアセテート共重合体およびポリオレフィンを溶融混合
する方法などの常法で製造することができる。The material used for the container of the present invention can be produced by a conventional method such as a method of melt-mixing an ethylene vinyl acetate copolymer and a polyolefin.
【００１１】本発明は、ポリオレフィンとしてポリエチ
レンを用いると容器の強度の点で好ましい。このときの
ポリエチレンとしては低密度および高密度のいずれのも
のでも用いることができる。In the present invention, it is preferable to use polyethylene as the polyolefin in view of the strength of the container. At this time, low-density and high-density polyethylenes can be used.
【００１２】本発明で用いる樹脂は、ビニルアセテート
基が素材全体の０．１〜１０重量％、好ましくは１〜３
重量％含まれているものが内容液の液出し性の点で好ま
しい。しかし、ビニルアセテート基の含量が高くなると
水分揮散が多くなるので１０重量％を越えて配合するこ
とは困難である。また、ビニルアセテート基が０．１重
量％未満であると液出し性の改善が満足できない。The resin used in the present invention has a vinyl acetate group in an amount of 0.1 to 10% by weight, preferably 1 to 3% by weight of the whole material.
What is contained by weight% is preferable in view of the liquid discharging property of the content liquid. However, when the content of the vinyl acetate group is high, the evaporation of water increases, so that it is difficult to mix the content exceeding 10% by weight. On the other hand, when the content of the vinyl acetate group is less than 0.1% by weight, the improvement of the liquid discharging property cannot be satisfied.
【００１３】本発明の一体成形型点眼剤用容器は、本発
明の効果を損なわない範囲で、素材の樹脂中に防腐剤、
抗菌剤、着色料などの成分を配合する事も可能である。[0013] The container for an integrally molded ophthalmic solution of the present invention contains a preservative and a preservative in the resin of the raw material as long as the effects of the present invention are not impaired.
It is also possible to mix components such as antibacterial agents and coloring agents.
【００１４】本発明の容器の内容液である点眼剤は、人
工涙液、一般点眼剤、抗菌点眼剤、洗眼剤などのいずれ
であってもよい。The eye drops which are the contents of the container of the present invention may be any of artificial tears, general eye drops, antibacterial eye drops, eyewash and the like.
【００１５】本発明において、内容液のｐＨは４．０〜
８．５が好ましい。また、内容液の成分は特に限定され
ない。In the present invention, the pH of the content liquid is 4.0 to 4.0.
8.5 is preferred. The components of the content liquid are not particularly limited.
【００１６】[0016]
【発明の効果】本発明により、スクイズ性、液出し性に
優れ、水分揮散の少ない、製造の容易な一体成形型の点
眼剤容器を提供することが可能となった。According to the present invention, it has become possible to provide an integrally formed ophthalmic solution container which is excellent in squeezing property and liquid discharging property, has little water evaporation, and is easy to manufacture.
【００１７】[0017]
【実施例】以下、実施例および試験例をあげ、本発明を
具体的に説明する。なお、実施例および比較例で製造し
た一体成形型点眼剤用容器は特開平８−３４４２２号公
報実施例に記載された容器と同様の方法で製造した。ま
た、容器の肉厚はすべて０．６ｍｍとなるようにした。The present invention will be described below in detail with reference to examples and test examples. The containers for the integrally molded ophthalmic solution produced in the examples and comparative examples were produced in the same manner as the containers described in the examples of JP-A-8-34422. The thickness of each container was set to 0.6 mm.
【００１８】実施例１ 塩化ナトリウム７５０ｍｇ、塩化カリウム９０ｍｇを滅
菌精製水９０ｍｌに溶解した後、ホウシャを適量加えて
ｐＨ７．４に調製し、滅菌精製水を加えて全量１００ｍ
ｌとし、点眼剤を調製した。Example 1 After dissolving 750 mg of sodium chloride and 90 mg of potassium chloride in 90 ml of sterilized purified water, the pH was adjusted to 7.4 by adding an appropriate amount of boiler, and sterile purified water was added to add a total of 100 m.
1 to prepare eye drops.
【００１９】上記点眼液をポリエチレンにビニルアセテ
ート基３重量％を配合した素材で製造した容器（内容量
１ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (1 ml in content) made of a material in which 3% by weight of a vinyl acetate group was mixed with polyethylene.
【００２０】実施例２ 塩化ナトリウム７５０ｍｇ、塩化カリウム９０ｍｇを滅
菌精製水９０ｍｌに溶解した後、リン酸水素二ナトリウ
ムを適量加えてｐＨを７．４に調製し、滅菌精製水を加
えて全量１００ｍｌとし、点眼剤を調製した。Example 2 After dissolving 750 mg of sodium chloride and 90 mg of potassium chloride in 90 ml of sterilized purified water, the pH was adjusted to 7.4 by adding an appropriate amount of disodium hydrogen phosphate, and the total volume was adjusted to 100 ml with sterilized purified water. And eye drops were prepared.
【００２１】上記点眼液をポリエチレンにビニルアセテ
ート基２重量％を配合した素材で製造した容器（内容量
１ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (1 ml in content) made of a material in which 2% by weight of a vinyl acetate group was mixed with polyethylene.
【００２２】実施例３ 塩化ナトリウム７５０ｍｇ、塩化カリウム９０ｍｇを滅
菌精製水９０ｍｌに溶解した後、炭酸水素ナトリウムを
適量加えてｐＨを７．４に調製し、滅菌精製水を加えて
全量１００ｍｌとし、点眼剤を調製した。Example 3 After dissolving 750 mg of sodium chloride and 90 mg of potassium chloride in 90 ml of sterilized purified water, the pH was adjusted to 7.4 by adding an appropriate amount of sodium hydrogen carbonate, and the total amount was adjusted to 100 ml with sterilized purified water. An agent was prepared.
【００２３】上記点眼液をポリエチレンにビニルアセテ
ート基１重量％を配合した素材で製造した容器（内容量
１ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (1 ml in internal volume) made of a material in which 1% by weight of a vinyl acetate group was mixed with polyethylene.
【００２４】実施例４ 実施例１で製造した点眼液をポリエチレンにビニルアセ
テート基０．５重量％を配合した素材で製造した容器
（内容量１ｍｌ）に充填した。Example 4 The ophthalmic solution prepared in Example 1 was filled into a container (1 ml in content) made of a material containing 0.5% by weight of a vinyl acetate group in polyethylene.
【００２５】実施例５ スルファメトキサゾールナトリウム４０００ｍｇ、リン
酸水素二ナトリウム１００ｍｇを滅菌精製水９０ｍｌに
溶解した後、０．１Ｎ−塩酸を適量加えてｐＨを８．２
に調製し、全量１００ｍｌとし、点眼液を調製した。Example 5 4000 mg of sodium sulfamethoxazole and 100 mg of disodium hydrogen phosphate were dissolved in 90 ml of sterilized purified water, and an appropriate amount of 0.1N hydrochloric acid was added to adjust the pH to 8.2.
To make a total volume of 100 ml to prepare eye drops.
【００２６】上記点眼液をポリエチレンにビニルアセテ
ート基２重量％を配合した素材で製造した容器（内容量
２ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (2 ml in content) made of a material in which 2% by weight of a vinyl acetate group was mixed with polyethylene.
【００２７】実施例６ タウリン１０００ｍｇ、グリチルリチン酸二カリウム２
５０ｍｇ、塩酸テトラヒドロゾリン２５ｍｇを滅菌精製
水９０ｍｌに溶解した後、ホウシャを適量加えてｐＨを
７．４に調製し、滅菌精製水を加えて全量１００ｍｌと
し、点眼剤を調製した。Example 6 Taurine 1000 mg, dipotassium glycyrrhizinate 2
After dissolving 50 mg and 25 mg of tetrahydrozoline hydrochloride in 90 ml of sterilized purified water, an appropriate amount of fuchsia was added to adjust the pH to 7.4, and sterilized purified water was added to make a total amount of 100 ml to prepare eye drops.
【００２８】上記点眼液をポリエチレンにビニルアセテ
ート基０．５重量％を配合した素材で製造した容器（内
容量０．５ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (0.5 ml in content) made of a material in which 0.5% by weight of a vinyl acetate group was mixed with polyethylene.
【００２９】実施例７ ビタミンＢ2５００ｍｇ、タウリン１０００ｍｇを滅菌
精製水９０ｍｌに溶解し、クエン酸でｐＨを５．５に調
製した後、滅菌精製水を加えて全量１００ｍｌとして点
眼剤を調製した。Example 7 500 mg of vitamin B 2 and 1000 mg of taurine were dissolved in 90 ml of sterilized purified water, the pH was adjusted to 5.5 with citric acid, and sterilized purified water was added to make a total amount of 100 ml to prepare eye drops.
【００３０】上記点眼液をポリエチレンにビニルアセテ
ート基０．５重量％を配合した素材で製造した容器（内
容量１ｍｌ）に充填した。The above-mentioned ophthalmic solution was filled in a container (1 ml in inner volume) made of a material in which 0.5% by weight of a vinyl acetate group was mixed with polyethylene.
【００３１】比較例１ 実施例１で製造した点眼液をポリエチレンで製造した容
器（内容量１ｍｌ）に充填した。Comparative Example 1 The ophthalmic solution prepared in Example 1 was filled in a container (1 ml in content) made of polyethylene.
【００３２】比較例２ 実施例６で製造した点眼液をポリエチレンで製造した容
器（内容量１ｍｌ）に充填した。Comparative Example 2 The ophthalmic solution prepared in Example 6 was filled in a container (1 ml in content) made of polyethylene.
【００３３】試験例１［液出し性試験］ （試験方法）実施例１〜７および比較例１、２のサンプ
ルについて、開封直後の内容液を１滴押し出す時の応力
［ｋｇ］をプッシュプルゲージ（SHIMPO製、DFG-20T）
を用いて測定した。Test Example 1 [Liquid Discharge Test] (Test Method) For the samples of Examples 1 to 7 and Comparative Examples 1 and 2, the stress [kg] at the time of pushing out one drop of the content liquid immediately after opening was measured by a push-pull gauge. (Manufactured by SHIMPO, DFG-20T)
It measured using.
【００３４】（結果）結果を表１に示した。(Results) The results are shown in Table 1.
【００３５】[0035]
【表１】 [Table 1]
【００３６】表１に示したようにポリエチレン容器では
比較例１、２のように内容液を押し出すのに大きな力を
要したが、本発明の容器（実施例１〜７）においては小
さい力で内容液を出すことができた。As shown in Table 1, the polyethylene container required a large force to extrude the content liquid as in Comparative Examples 1 and 2, whereas the container of the present invention (Examples 1 to 7) required a small force. The content liquid could be discharged.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 ▲高▼田 純子 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 ────────────────────────────────────────────────── ─── Continued on the front page (72) Inventor ▲ Taka ▼ Junko 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
セテート共重合体を配合した樹脂からなる一体成形型点
眼剤用容器。1. An integrally molded ophthalmic container made of a resin containing a polyolefin and an ethylene vinyl acetate copolymer.
求項１記載の一体成形型点眼剤用容器。2. The ophthalmic solution container according to claim 1, wherein the polyolefin is polyethylene.
〜１０重量％である請求項１または２に記載の一体成形
型点眼剤用容器。3. The method according to claim 1, wherein the vinyl acetate group is 0.1% of the container material.
3. The container for an integrally molded ophthalmic solution according to claim 1, wherein the amount is 10 to 10% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8244359A JPH1085303A (en) | 1996-09-17 | 1996-09-17 | Integrally-formed container for eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8244359A JPH1085303A (en) | 1996-09-17 | 1996-09-17 | Integrally-formed container for eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1085303A true JPH1085303A (en) | 1998-04-07 |
Family
ID=17117529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8244359A Pending JPH1085303A (en) | 1996-09-17 | 1996-09-17 | Integrally-formed container for eye drops |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1085303A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370281A (en) * | 2011-11-11 | 2012-03-14 | 许昌恒源发制品股份有限公司 | Men's toupee with additional high-simulation skin at front edge of elastic net and preparation process thereof |
-
1996
- 1996-09-17 JP JP8244359A patent/JPH1085303A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370281A (en) * | 2011-11-11 | 2012-03-14 | 许昌恒源发制品股份有限公司 | Men's toupee with additional high-simulation skin at front edge of elastic net and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0814748B1 (en) | Container for pharmaceuticals containing chlorobutanol | |
| JP7494351B2 (en) | Ophthalmic Pharmaceutical Products | |
| CN107049929B (en) | Single dose pharmaceutical formulations of thyroid hormones T3 and/or T4 | |
| JP2018002733A (en) | Dibutylhydroxytoluene-containing preparation, and method for stabilizing dibutylhydroxytoluene | |
| WO2013065720A1 (en) | Ophthalmological aqueous composition | |
| AU696480B2 (en) | Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate | |
| JPH1085303A (en) | Integrally-formed container for eye drops | |
| JP6532959B2 (en) | Ophthalmic composition | |
| KR100307846B1 (en) | Polymer Compositions Used in Physiological Tear Compositions | |
| JP4806956B2 (en) | Ophthalmic solution | |
| AU2012213180B2 (en) | Improvements in and relating to compositions | |
| US3992215A (en) | Pharmaceutical suspension for opaqing empty gelatin capsules | |
| TW202135821A (en) | Aqueous composition | |
| GB2298365A (en) | A Pharmaceutical Liquid Comprising Potassium Bicarbonate and Sodium Alginate | |
| EP0221699B1 (en) | Composition for the treatment of infections | |
| PT2207419E (en) | Foam stabilizer for a sterilization composition | |
| CN109069421B (en) | Ophthalmic composition | |
| CN106580941B (en) | A kind of powder and preparation method thereof of gargling containing sodium azulenesulfonate | |
| EP4262874A1 (en) | Instantly gelling compositions for artificial saliva and ultrasound gels | |
| JPH11319028A (en) | Eye drops | |
| JP2022176963A (en) | ophthalmic composition | |
| RU2173139C2 (en) | Improvements of organic compositions or improvements related to these compositions | |
| CA2214343C (en) | Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate | |
| JP2023030691A (en) | ophthalmic composition | |
| JPH1085304A (en) | Container for fat-soluble vitamins and method for preventing their adsorption to the container |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051129 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060509 |